NTRK1 and neoplasm: Dovitinib, an inhibitor of multiple receptor tyrosine kinases, is reported to induce the activation of tumor‐intrinsic SNAI1/2‐IFN‐γ signaling and suppress EMT in another recent study, which promotes T cell recruitment and makes mesenchymal‐like tumor to be sensitive to CTLA4 blockade.229